CSL Behring Reports Global Stockout of Hemophilia B Gene Therapy

March 27, 2026

CSL Behring recently announced a temporary global stockout of etranacogene dezaparvovec-drlb, Hemgenix), an FDA-approved gene therapy for hemophilia B, delaying treatment for some patients in markets with established access. The company said the disruption is not related to safety or efficacy but reflects the complexity of manufacturing gene therapies.